A high-throughput drug screening strategy against coronaviruses

Area of Science:

• Virology
• Drug Discovery
• Molecular Biology

Background:

• Coronaviruses (CoV) pose significant global health threats, causing epidemics and pandemics like COVID-19.
• The urgent need for effective treatments against SARS-CoV-2 and other CoV strains persists despite vaccine development.
• Existing containment measures for highly pathogenic CoV can impede rapid drug screening.

Purpose of the Study:

• To establish a high-throughput screening strategy for identifying broad-spectrum antiviral drugs against coronaviruses.
• To leverage milder CoV strains (HCoV-OC43, MHV) for efficient drug discovery, circumventing stringent biosafety requirements.
• To develop a system for rapid evaluation of potential SARS-CoV-2 therapeutics.

Main Methods:

• Engineered HCoV-OC43 and MHV with a luciferase reporter gene to quantify viral activity.
• Screened large compound libraries for antiviral activity against engineered HCoV-OC43 and MHV.
• Evaluated promising drug candidates against SARS-CoV-2 following structural optimization.

Main Results:

• Developed a functional luciferase reporter system for HCoV-OC43 and MHV to measure antiviral efficacy.
• Identified compounds demonstrating activity against both HCoV-OC43 and MHV.
• Established a pipeline for further testing of identified compounds against SARS-CoV-2.

Conclusions:

• The developed high-throughput screening system enables rapid identification of broad-spectrum antiviral drugs for coronaviruses.
• This approach offers a safer and more efficient alternative for discovering potential treatments for SARS-CoV-2 and future CoV outbreaks.
• The strategy provides a valuable tool for accelerating the development of clinical management options against CoV infections.